以岭药业丰富产品研发管线 化药专利新药苯胺洛芬注射液获批上市

Core Viewpoint - Yiling Pharmaceutical has achieved a dual benefit with the approval of its new drug, Anilinofen Injection, and a positive profit forecast for 2025, marking a significant step in its transition to a dual-driven model of traditional Chinese medicine and chemical drugs [1][2]. Group 1: Financial Performance - Yiling Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan for 2025, successfully turning a profit [1]. - The company has maintained high R&D investment, with 544 million yuan spent in the first three quarters of 2025, accounting for 9.27% of its revenue [2]. Group 2: Product Development - Anilinofen Injection is the first patented chemical drug developed by Yiling Wanzhou and is aimed at the postoperative analgesia market [1]. - The approval of Anilinofen Injection enhances the company's product pipeline and is expected to contribute to new cash flow, supporting further R&D investments [2]. Group 3: Market Opportunity - The postoperative analgesia market is experiencing rapid growth, with 104 million surgical procedures expected in 2024, an 8% increase from 2023 [1]. - The approval of Anilinofen Injection provides a new treatment option for postoperative pain management, aligning with clinical guidelines emphasizing the role of non-steroidal anti-inflammatory drugs [1]. Group 4: Strategic Direction - Yiling Pharmaceutical has established a "one body, two wings" strategy, focusing on traditional Chinese medicine while expanding into chemical drugs and health products [3]. - The approval of Anilinofen Injection signifies a key milestone in the company's strategy, transitioning from a traditional Chinese medicine leader to a comprehensive pharmaceutical enterprise [3].